Characteristics of Ophthalmology Trials Registered in ClinicalTrials.gov, 2007-2018.
To perform a comprehensive analysis of characteristics of ophthalmology trials registered in ClinicalTrials.gov. Cross-sectional study METHODS: All 4,203 ophthalmologic clinical trials registered on ClinicalTrials.gov between October 1, 2007, and April 30, 2018 were identified using Medical Subject Heading (MeSH) terms. Disease condition terms were verified by manual review. Trial characteristics were assessed through frequency calculations. Hazard ratio and 95% confidence intervals were determined for characteristics associated with early discontinuation. The majority of trials were multi-armed (73.6%), single-site (69.4%), randomized (64.8%), and had <100 enrollees (66.3%). Thirty-three percent utilized a data monitoring committee (DMC), and 50.6% incorporated blinding. 51.6% were funded by industry, while 2.6% by the National Institute of Health (NIH). NIH trials were significantly more likely to address oncologic (NIH=15.5%, Other=3%, Industry=1.5%; p<0.001) or pediatric disease (NIH=20.9%, Other=5.9%, Industry=1.4%; p<0.001). Industry-sponsored trials (69.6% of phase 3 trials) and were significantly more likely to be randomized (Industry=68.7%, NIH=58.9%, Other=60.8%; p<0.001) and blinded (Industry=57.2%, NIH=42.7%, Other=43.5%; p<0.001). 359 trials (8.5%) were discontinued early and 530 trials (12.6%) had unknown status. Trials were less likely to be discontinued if funded by sources other than industry (HR 0.72; 95% CI 0.55-0.95; p=0.021) and/or had a DMC (HR 0.71, 95% CI 0.55-0.92, p=0.010). Ophthalmology trials in the past decade reveal heterogeneity across study funding sources. NIH trials were more likely to support historically underfunded subspecialties, while Industry trials were more likely to face early discontinuation. These trends emphasize the importance of carefully monitored and methodologically-sound trials with deliberate funding allocation.